Future oncology最新文献

Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.

IF 3 4区医学

Future oncology Pub Date : 2025-04-08 DOI: 10.1080/14796694.2025.2488635

Sydney Stern, Patrick F McKenzie, Nicholas Bernthal, Shannon O'Neill, Emanuela Palmerini, R Lor Randall, William Tap, Thomas Scharschmidt, Sara Rothschild

{"title":"Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.","authors":"Sydney Stern, Patrick F McKenzie, Nicholas Bernthal, Shannon O'Neill, Emanuela Palmerini, R Lor Randall, William Tap, Thomas Scharschmidt, Sara Rothschild","doi":"10.1080/14796694.2025.2488635","DOIUrl":"https://doi.org/10.1080/14796694.2025.2488635","url":null,"abstract":"Background: Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive neoplasm that adversely impact patients' physical function and quality of life (QoL). This cross-sectional analysis leverages real-world data from the TGCT Support Patient Registry to elucidate the patient experience with TGCT and the disease burden across healthcare systems.Research design and methods: A total of 497 patients from 32 countries, 71.4% (n = 355) with diffuse-TGCT (D-TGCT), 18.9% (n = 94) with localized TGCT (L-TGCT), and 9.7% (n = 28) with unspecified TGCT were included in this cross-sectional analysis of the TGCT Support Registry.Results: A majority of patients (61.2%, n = 304) were diagnosed by orthopedic/sports medicine surgeons, half (n = 248) were misdiagnosed prior to their TGCT diagnosis, and 32% (n = 278) of patients were diagnosed > 24 months following symptom onset. 79.1% (n = 393) of all patients had ≥ 1 resection and 63% of those patients reported ≥ 1 recurrence. Of those patients that had recurrence following resection, 59% had ≥ 2 recurrences. 23% of patients (n = 115) changed occupations or prematurely retired due to TGCT and the proportion of patients increased with > 2 surgeries.Conclusion: Greater awareness of TGCT among HCPs is needed to facilitate diagnosis and referral to multidisciplinary teams is warranted to reduce recurrence rates, number of surgical interventions, and improve QoL.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.

IF 3 4区医学

Future oncology Pub Date : 2025-04-06 DOI: 10.1080/14796694.2025.2480050

Jason Hafron, Agnes Hong, Michael J Ryan, Hela Romdhani, Frédéric Kinkead, Scott C Flanders, Rana R McKay

{"title":"Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.","authors":"Jason Hafron, Agnes Hong, Michael J Ryan, Hela Romdhani, Frédéric Kinkead, Scott C Flanders, Rana R McKay","doi":"10.1080/14796694.2025.2480050","DOIUrl":"https://doi.org/10.1080/14796694.2025.2480050","url":null,"abstract":"Aims: Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022).Methods: The IBM MarketScan Research Database (1 January 2017 - 31 December 2022) was used for enrollment history and claims. ADT adherence was measured by the proportion of days covered (PDC) at 3, 6, and 12 months, calculated as days on ADT divided by period duration. Kaplan-Meier analysis assessed treatment persistence by measuring time to treatment discontinuation.Results: Relugolix had higher adherence (PDC ≥ 80%) at 12 months (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%). Median time to discontinuation was also longer for relugolix (13.5 months) than degarelix (3.1 months) and GnRH agonists (8.8 months). Persistence and adherence rates were higher in metastatic prostate cancer.Conclusions: Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas.

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-02-07 DOI: 10.1080/14796694.2025.2463881

Tarek Assi, Axel Le Cesne

引用次数: 0

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-03-06 DOI: 10.1080/14796694.2025.2468578

Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Aref Al-Kali, H Joachim Deeg, Mitchell Sabloff, Mary-Margaret Keating, Nancy Zhu, Nashat Y Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Amy E DeZern, Casey L O'Connell, Gail J Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Brian Leber, Aditi Shastri, Aram Oganesian, Harold N Keer, Mohammad Azab, Michael R Savona

引用次数: 0

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. 超越现状：当疾病体积和转移时间不足以对 mHSPC 进行个性化治疗时。

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI: 10.1080/14796694.2025.2468569

Ángel Borque-Fernando, Teresa Alonso-Gordoa, María José Juan-Fita, Fernando Lopez Campos, Daniel Adolfo Pérez-Fentes, Antoni Vilaseca, Cristina Moretones Agut, Paola Usán, Pablo Maroto Rey

引用次数: 0

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-02-28 DOI: 10.1080/14796694.2025.2470604

Maximilian Marhold, Marta Vaz Batista, Isabel Blancas, Cristina Morales, Cristina Saura-Manich, Cristina Saavedra, Manuel Ruíz-Borrego, Patricia Cortez, Felipe Slebe, Marta Campolier, Juliana Carvalho Santos, José Antonio Guerrero-Martínez, Carlos Jiménez-Cortegana, Beate Rottenmanner, Heidrun Forstner, Rupert Bartsch, Matthias Preusser

引用次数: 0

The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer.

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1080/14796694.2025.2470108

Neal D Shore, Daniel J George, Daniel E Spratt, Jose De La Cerda

引用次数: 0

Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis. 非小细胞肺癌患者使用无性淋巴瘤激酶抑制剂的心血管毒性：网络荟萃分析。

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2024-10-14 DOI: 10.1080/14796694.2024.2370239

Jia Qin Cai, Yi Ming Wang, Xinmiao Lin, Mumu Xie, Guifeng Zhang, Xiao Xia Wei, Hong Sun

引用次数: 0

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-02-11 DOI: 10.1080/14796694.2025.2463798

Gregory M Cote, Sant P Chawla, George Demetri, Bernd Kasper, Robin L Jones, Javier Martin Broto, Joseph Wooley, Mia C Weiss, Salvatore Tafuto, Giuseppe Badalamenti, Irene Carrasco, Paloma Peinado, Jean-Yves Blay, Gaston Boggio, Cristian Fernandez, Antonio Nieto, Carmen Kahatt, Vicente Alfaro, Axel Le Cesne

{"title":"SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.","authors":"Gregory M Cote, Sant P Chawla, George Demetri, Bernd Kasper, Robin L Jones, Javier Martin Broto, Joseph Wooley, Mia C Weiss, Salvatore Tafuto, Giuseppe Badalamenti, Irene Carrasco, Paloma Peinado, Jean-Yves Blay, Gaston Boggio, Cristian Fernandez, Antonio Nieto, Carmen Kahatt, Vicente Alfaro, Axel Le Cesne","doi":"10.1080/14796694.2025.2463798","DOIUrl":"10.1080/14796694.2025.2463798","url":null,"abstract":"Previous phase I/II trials indicate promising activity of lurbinectedin plus doxorubicin (DOX) in leiomyosarcoma (LMS). We describe here the rationale and design of SaLuDo, an open label, randomized, multicenter, seamless phase IIb/III study to evaluate the antitumor activity and safety of lurbinectedin plus DOX versus DOX alone in the first-line setting of metastatic LMS. The phase IIb stage will evaluate two schedules of the combination for the phase III stage given every 3 weeks (q3wk): DOX 50 mg/m2 plus lurbinectedin 2.2 mg/m2, and DOX 25 mg/m2 plus lurbinectedin 3.2 mg/m2. The control arm will be DOX 75 mg/m2 q3wk. The primary endpoint is progression-free survival by independent review; overall survival is the key secondary endpoint. Clinical trial registration: www.clinicaltrials.gov identifier is NCT06088290.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"943-951"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic treatment patterns and adherence to guidelines in Japanese patients with metastatic non-small cell lung cancer.

IF 3 4区医学

Future oncology Pub Date : 2025-04-01 Epub Date: 2025-02-28 DOI: 10.1080/14796694.2025.2470611

Keiko Nishimyo, Shunya Ikeda, Kiyohide Fushimi, Tsutomu Yamazaki, Koichi B Ishikawa

{"title":"Systemic treatment patterns and adherence to guidelines in Japanese patients with metastatic non-small cell lung cancer.","authors":"Keiko Nishimyo, Shunya Ikeda, Kiyohide Fushimi, Tsutomu Yamazaki, Koichi B Ishikawa","doi":"10.1080/14796694.2025.2470611","DOIUrl":"10.1080/14796694.2025.2470611","url":null,"abstract":"Background: Non-small-cell-lung cancer (NSCLC) medication use and guideline adherence remain unclear. We investigated treatment patterns and adherence among Japanese patients with NSCLC.Research design and methods: We analyzed treatment patterns and guideline adherence by age and histology in ≥ 20-year-olds with stage IV NSCLC treated between 2016-2018 using diagnostic procedure combination data. Logistic regression analysis evaluated the impact of various factors on guideline adherence.Results: We included 9,722 patients. In < 75-year-olds with nonsquamous NSCLC, first-to third-line treatments comprised 31.8% platinum combination therapy, 26.3% immune checkpoint inhibitors, and 62.5% cytotoxic chemotherapy. In ≥ 75-year-olds, first-line and second-line molecular targeted therapies represented 46.6% and 35.6%, whereas third-line cytotoxic chemotherapy represented 42.3%. In squamous NSCLC, first-line platinum combination therapy was predominant (69.7% and 47.7% for < 75-and ≥75-year-olds). The most common second-line and third-line therapies were immune checkpoint inhibitors (48.6% and 50.8% for < 75-and ≥75-year-olds) and cytotoxic chemotherapy (62.5% and 55.2% for < 75-and ≥75-year-olds), respectively. The highest guideline adherence (90%) was in < 75-year-olds with squamous NSCLC. Age, histology, activities of daily living, and cumulative hospitalizations over the past 18 months influenced treatment adherence.Conclusion: New NSCLC drug introduction increased regardless of age, suggesting prognosis improvement. More efficient drug application and broader guideline dissemination are required.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1101-1111"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0